학제간연구 | Interdisciplinary Studies in Gambling | 跨学科研究
- date : 2015-05-20 01:10|hit : 1385
-
- Article] Model-specific effects of bumetanide on epileptiform activity in the in-vitro intact hippocampus of the newborn mouse
-
DocNo of ILP: 4160
Doc. Type: Article
Title: Model-specific effects of bumetanide on epileptiform activity in the in-vitro intact hippocampus of the newborn mouse
Authors: Kilb, W; Sinning, A; Luhmann, HJ
Full Name of Authors: Kilb, W.; Sinning, A.; Luhmann, H. J.
Keywords by Author: seizure; perinatal epilepsy; in-toto preparation; NKCC1; chloride homeostasis; immature brain
Keywords Plus: DEVELOPING BRAIN; RAT NEOCORTEX; SEIZURES; POTASSIUM; EPILEPSY; COTRANSPORT; INHIBITION; MATURATION; NEURONS; NKCC1
Abstract: The immature brain has a higher susceptibility to develop seizures, which often respond poorly to classical pharmacological treatment. It has been recently suggested that bumetanide, which blocks Na+-dependent K+-Cl--cotransporter isoform 1 (NKCC1) and thus attenuates depolarizing GABAergic responses, could soothe epileptiform activity in immature nervous systems. To evaluate whether bumetanide consistently attenuates epileptiform activity, we investigated the effect of 10 mu M bumetanide in five different in-vitro epilepsy models using field potential recordings in the CA3 region of intact mouse hippocampal preparations at postnatal day 4-7. Bumetanide reduced amplitude and frequency of ictal-like events (ILE) induced by 8.5 mM K+, but it increased the frequency of ILE induced by 1 mu M kainate. Inhibition of ligand-gated Cl- channels by 10 mu M gabazine and 30 mu M strychnine induced interictal activity (IA) that was only marginally affected by bumetanide. Removal of extracellular Mg2+ induced both ILE and IA. Bumetanide had no effect on these ILE but enhanced the IA. Low-Mg2+ solution containing 20 mu M 4-AP induced late-recurrent discharges, which were slightly attenuated by bumetanide. In summary, our results demonstrate that bumetanide exerts diverse effects in different in-vitro epilepsy models. (C) 2007 Elsevier Ltd. All rights reserved.
Cate of OECD: Basic medicine
Year of Publication: 2007
Business Area: other
Detail Business: medicine & science
Country: England
Study Area: development, development
Name of Journal: NEUROPHARMACOLOGY
Language: English
Country of Authors: Univ Mainz, Inst Pathophysiol & Physiol, D-55128 Mainz, Germany
Press Adress: Kilb, W (reprint author), Univ Mainz, Inst Pathophysiol & Physiol, Duesbergweg 6, D-55128 Mainz, Germany.
Email Address: wkilb@uni-mainz.de
Citaion:
Funding:
Lists of Citation: BARAM TZ, 1990, DEV BRAIN RES, V57, P291, DOI 10.1016/0165-3806(90)90055-4; Dulac Olivier, 1995, P289; Dzhala VI, 2003, J NEUROSCI, V23, P7873; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Fukuda A, 2005, NAT MED, V11, P1153, DOI 10.1038/nm1105-1153; HABLITZ JJ, 1987, DEV BRAIN RES, V36, P299, DOI 10.1016/0165-3806(87)90036-8; Holmes GL, 2002, NEUROREPORT, V13, pA3, DOI 10.1097/00001756-200201210-00002; Holmes GL, 1997, EPILEPSIA, V38, P12, DOI 10.1111/j.1528-1157.1997.tb01074.x; JAVAHERI S, 1993, J NEUROCHEM, V61, P1525, DOI 10.1111/j.1471-4159.1993.tb13648.x; Khalilov I, 1997, EUR J PHARMACOL, V319, pR5, DOI 10.1016/S0014-2999(96)00964-8; Khalilov I, 1999, EUR J NEUROSCI, V11, P3468, DOI 10.1046/j.1460-9568.1999.00768.x; Khalilov I, 1997, NEURON, V19, P743, DOI 10.1016/S0896-6273(00)80956-3; Kilb W, 2006, J NEUROSCI RES, V84, P119, DOI 10.1002/jnr.20871; Kirchner A, 2003, EPILEPSIA, V44, P1145, DOI 10.1046/j.1528-1157.2003.01603.x; KORN SJ, 1987, J NEUROPHYSIOL, V57, P325; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247; MCBAIN CJ, 1994, J NEUROPHYSIOL, V72, P2853; MILES R, 1984, NEUROSCIENCE, V12, P1179, DOI 10.1016/0306-4522(84)90012-5; Moser J, 2006, BRAIN RES, V1077, P170, DOI 10.1016/j.brainres.2006.01.024; Rohrbough J, 1996, J NEUROSCI, V16, P82; Russell JM, 2000, PHYSIOL REV, V80, P211; Sanchez RM, 2001, EPILEPSIA, V42, P577, DOI 10.1046/j.1528-1157.2001.12000.x; Sykova E, 2004, NEUROSCIENCE, V129, P861, DOI 10.1016/j.neuroscience.2004.06.077; Wells JE, 2000, J NEUROSCI, V20, P8822; Yamada J, 2004, J PHYSIOL-LONDON, V557, P829, DOI 10.1113/jphysiol.2004.062471; ZHANG CL, 1994, EPILEPSIA S, V35, P68
Number of Citaion: 26
Publication: PERGAMON-ELSEVIER SCIENCE LTD
City of Publication: OXFORD
Address of Publication: THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
ISSN: 0028-3908
29-Character Source Abbreviation: NEUROPHARMACOLOGY
ISO Source Abbreviation: Neuropharmacology
Volume: 53
Version: 4
Start of File: 524
End of File: 533
DOI: 10.1016/j.neuropharm.2007.06.015
Number of Pages: 10
Web of Science Category: Neurosciences; Pharmacology & Pharmacy
Subject Category: Neurosciences & Neurology; Pharmacology & Pharmacy
Document Delivery Number: 219RW
Unique Article Identifier: WOS:000250103300007
- reply : 0
-
- list
-
- prev
- next